Company sells common shares, three-year warrants in brokered offering
By Devika Patel
Knoxville, Tenn., Jan. 13 – Aldeyra Therapeutics, Inc. said it will raise $7.79 million in a private placement of stock. Laidlaw & Co. (UK) Ltd. is the agent.
The company will sell 1,113,080 common shares at $7.00 per share. The purchase price is a 10.49% discount to the Jan. 12 closing share price of $7.82.
Investors also will receive warrants for 1,113,080 shares. The warrants are each exercisable at $9.50 for three years. The strike price is a 21.48% premium to the Jan. 12 closing share price.
Perceptive Advisors LLC was the lead investor. Knoll Capital, Sphera Global Healthcare Fund, DAFNA Capital also participated.
Proceeds will be used for upcoming Phase 2 clinical trials in Sjogren-Larsson Syndrome and noninfectious anterior uveitis, working capital and general corporate purposes.
The biotechnology company is based in Burlington, Mass.
| Issuer: | Aldeyra Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $7,791,560
|
| Shares: | 1,113,080
|
| Price: | $7.00
|
| Warrants: | For 1,113,080 shares
|
| Warrant expiration: | Three years
|
| Warrant strike price: | $9.50
|
| Agent: | Laidlaw & Co. (UK) Ltd.
|
| Investors: | Perceptive Advisors LLC (lead), Knoll Capital, Sphera Global Healthcare Fund, DAFNA Capital
|
| Announcement date: | Jan. 12
|
| Stock symbol: | Nasdaq: ALDX
|
| Stock price: | $7.82 at close Jan. 9
|
| Market capitalization: | $47.27 million
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
